Extramedullary plasmacytoma
diseaseOn this page
Also known as EPextramedullary plasmacytoma (clinical)extraosseous plasmacytomaplasmacytoma, extramedullaryplasmacytoma, extramedullary (not occurring in bone)
Summary
Extramedullary plasmacytoma (MONDO:0002754) is a disease and 11 clinical trials. Top therapeutic interventions include foscarnet, beclomethasone dipropionate, and ganciclovir. A subtype of plasmacytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | extramedullary plasmacytoma |
| Mondo ID | MONDO:0002754 |
| DOID | DOID:3720 |
| ICD-10-CM | C90.2 |
| ICD-11 | 246947217 |
| NCIT | C4002 |
| SNOMED CT | 188718006 |
| UMLS | C0278619 |
| MedGen | 75843 |
| GARD | 0023233 |
| Is cancer (heuristic) | no |
Also known as: EP · extramedullary plasmacytoma · extramedullary plasmacytoma (clinical) · extraosseous plasmacytoma · plasmacytoma, extramedullary · plasmacytoma, extramedullary (not occurring in bone)
Disease family
This is a subtype of plasmacytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm › plasmacytoma › extramedullary plasmacytoma
Related subtypes (4): solitary osseous plasmacytoma, solitary plasmacytoma of chest wall, primary plasmacytoma of the bone, extramedullary soft tissue plasmacytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2 | 3 |
| PHASE1 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02336386 | PHASE3 | UNKNOWN | CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma |
| NCT04166565 | PHASE2 | ACTIVE_NOT_RECRUITING | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease |
| NCT00489203 | PHASE2 | COMPLETED | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
| NCT01849783 | PHASE2 | COMPLETED | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT01588015 | PHASE1 | COMPLETED | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| NCT01199562 | Not specified | ACTIVE_NOT_RECRUITING | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant |
| NCT00112593 | Not specified | COMPLETED | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
| NCT01053494 | Not specified | COMPLETED | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
| NCT04008888 | Not specified | UNKNOWN | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FOSCARNET | 4 | 4 |
| BECLOMETHASONE DIPROPIONATE | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| TACROLIMUS ANHYDROUS | 4 | 1 |
| VALGANCICLOVIR | 4 | 1 |
| CHEMBL1319520 | 0 | 1 |